Axsome Therapeutics Appoints World Leading Experts to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Axsome Therapeutics Appoints World Leading Experts to Depression Scientific Advisory Board

NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the treatment of pain and other central nervous system (CNS) disorders, today announced the formation of its Depression Scientific Advisory Board ("Depression SAB") comprised of leading experts in the areas of depression, U.S. Food and Drug Administration (FDA) regulations, and clinical trial design. These experts will provide key scientific, clinical, and strategic guidance concerning Axsome's development programs in depression and other CNS disorders.

The following members have been appointed to Axsome's Depression SAB:

  • Maurizio Fava, M.D., Director of the Clinical Research Program, Executive Vice Chair of the Department of Psychiatry, at Massachusetts General Hospital (MGH); Slater Family Professor of Psychiatry, at Harvard Medical School.
     
  • Thomas Laughren, M.D., Division Director (retired) for the Division of Psychiatry Products, at the U.S. Food and Drug Administration (FDA).
     
  • Dan Iosifescu, M.D., Director of the Mood and Anxiety Disorders Program, Associate Professor of Psychiatry and Neuroscience, at the Icahn School of Medicine at Mount Sinai; Consultant in Psychiatry at Massachusetts General Hospital (MGH).

"We are honored that Drs. Fava, Laughren, and Iosifescu have accepted our invitation to join Axsome's Depression Scientific Advisory Board," said Herriot Tabuteau, M.D., Axsome's Chief Executive Officer. "We welcome their unparalleled clinical, research and regulatory knowledge, and look forward to continuing to work with them as we advance our product candidates."

Axsome Depression Scientific Advisory Board Member Biographies:

Maurizio Fava, M.D.

Dr. Maurizio Fava is the Director of the Clinical Research Program, Executive Vice Chair of the Department of Psychiatry, and Executive Director of the Clinical Trials Network and Institute, at Massachusetts General Hospital (MGH); and the Slater Family Professor of Psychiatry at Harvard Medical School. Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 600 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 500 abstracts. Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at the MGH. He founded and was Director of the hospital's Depression Clinical and Research Program from 1990 until 2014. In 2007, he also founded and is now the Executive Director of the MGH Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry. Under Dr. Fava's direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. Dr. Fava's prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies. Dr. Fava has received several awards during his career and is on the editorial board of five international medical journals.

Thomas P. Laughren, M.D.

Dr. Thomas Laughren was Division Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at FDA until 2012. As Division Director for the Division of Psychiatry Products, Dr. Laughren oversaw the review of all psychiatric drug development activities conducted under INDs (Investigational New Drug Applications) and the review of all NDAs (New Drug Applications) and supplements for new psychiatric drug claims. He has authored and co-authored numerous papers and book chapters on regulatory and methodological issues pertaining to the development of psychiatric drugs, and is a frequent speaker at professional meetings on these same topics. Prior to joining the FDA in September 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, Rhode Island, and was on the faculty of the Brown University Program in Medicine. He received his medical degree from the University of Wisconsin in Madison, Wisconsin, and also completed residency training in psychiatry at the University of Wisconsin. Dr. Laughren is board certified in general psychiatry. Dr. Laughren has received numerous awards for his regulatory accomplishments. He is currently a consultant in psychiatric drug development.

Dan V. Iosifescu, M.D.

Dr. Dan Iosifescu is the Director of the Mood and Anxiety Disorders Program and Associate Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai. Dr. Iosifescu's research is focused on novel pharmacological treatment modalities (such as ketamine and other glutamatergic drugs), and on biological markers of treatment outcome in mood disorders, using neuroimaging and neurophysiology techniques to investigate structural, biochemical, and functional brain abnormalities in mood disorders and their impact on clinical treatment. After receiving his M.D. from the Institute of Medicine and Pharmacy in Bucharest, Romania, Dr. Iosifescu completed his internship and psychiatry residency at Massachusetts General Hospital (MGH) and McLean Hospital, serving as chief resident in consultation-liaison psychiatry. His research training included a neuroimaging fellowship in the Neuroscience Laboratory at Harvard Medical School, a psychopharmacology fellowship in the MGH Mood and Anxiety Disorders Institute, and a fellowship in the Clinical Investigator Training Program at Harvard and MIT. In parallel Dr. Iosifescu received a Master of Medical Science degree from Harvard University. Until April 2010, he was Associate Professor of Psychiatry at Harvard Medical School and Director of Translational Neuroscience in the Depression Clinical and Research Program and Site Director of the Bipolar Trials Network, both at MGH. Dr. Iosifescu has authored more than 100 papers in peer-reviewed medical journals, 14 book chapters and more than 100 abstracts. He has received a series of prestigious awards: the NARSAD Young Investigator Award (which he received twice), the Kaplen Award and the Livingston Award from Harvard Medical School, the APA Young Investigator Award, the NCDEU New Investigator Award, and a NIMH K23 Career Development Award.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of pain and other CNS disorders. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products, which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.

Axsome Contact: Mark Jacobson Senior Director of Operations Axsome Therapeutics, Inc. 45 Rockefeller Plaza, 20th Floor New York, NY 10111 Tel: 212-332-3243 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 302

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Energy: Upgrading America's Aging Power Grid

Updated Category News Views 219

The Energy Conundrum Let’s face it, folks, the electric grid we’re using is like a beat-up old car—driving it won’t get any easier unless we pour in some cash and elbow grease. We all know increasing demand for power is putting the squeeze on the infrastructure, and everybody from policymakers to average homeowners is feeling the pinch. Do a little research (or...

Continue Reading
Cove Capital Investments Boosts Annual Distribution Rates Again

Updated Category News Views 69

Cove Capital Investments Announces Distribution Rate Increase The recent announcement regarding the increase in distribution rates by Cove Capital Investments highlights the success of its unique value-add strategy. This strategy is elaborated in the Private Placement Memorandum when the multifamily offering was made available to accredited investors. Performance of Cove...

Continue Reading
Broadcom Surges in After-Hours Trading on Stellar Earnings

Updated Category News Views 268

Broadcom Inc Reports Strong Earnings Broadcom Inc (NASDAQ: AVGO) experienced a remarkable 12.82% increase in its shares during after-hours trading after unveiling its first-quarter results. This rally followed a 6.33% decline during the regular trading hours, which was part of a larger trend of selloffs in the artificial intelligence (AI) chip market. Significant...

Continue Reading
Recent Downgrades: Analysts Weigh In on Key Stocks

Updated Category News Views 162

Analysts' Outlook on Key Stocks Recent changes from top Wall Street analysts revealed a shift in outlook on several prominent companies. Their evaluations often impact market trends and investor sentiment towards various stocks. Invivyd Inc Downgraded D. Boral Capital's Jason Kolbert downgraded the rating for Invivyd Inc (NASDAQ: IVVD) from Buy to Hold. On the trading...

Continue Reading
Innovative Grip Module Redefines Firearm Handling Experience

Updated Category News Views 299

Revolutionizing Firearm Grip with Innovative Design In the realm of firearm accessories, innovation often leads to transformative user experiences. One such breakthrough comes in the form of the 2911 Grip Module. This specially designed grip module addresses the common issues faced by firearm enthusiasts, offering a solution that enhances both comfort and usability. What...

Continue Reading